USDA approves drug for canine allergic and atopic dermatitisJanuary 6, 2026Befrena (tirnovetmab), an anti–IL-31 monoclonal antibody injection for the treatment of canine allergic and atopic dermatitis, is intended for use in dogs of any age and is recommended at dosing intervals of six to eight weeks following treatment.
SPONSORED CONTENTIs your parasite protocol missing something?Adding Hill's GI nutrition to your parasite protocol supports GI healing for more complete diarrhea management than medication alone. + Learn More
Vet techs' role in diabetes educationJanuary 6, 2026Empowering our veterinary technicians to educate and train clients is a team-based approach to diabetes mellitus (DM) management. This enables our clients to feel capable and confident in managing their pets’ at-home care.
A look at advanced techniques in minimally invasive tooth extractionJanuary 6, 2026Successful application of these tools depends on proper case selection, familiarity with anatomy, and use of appropriate instrumentation.
VPN Plus+ ExclusiveNeonatal Care and ResuscitationJanuary 2, 2026In this session: Marco Bregliano, DVM, DACT, covers normal neonatal parameters and specific neonatal care needs, as well as understanding neonatal care resuscitation, and the necessary supplies and equipment for resuscitation.
Providing therapeutic options to manage canine atopic dermatitisDecember 30, 2025Veterinarians need a solid understanding of the available therapeutic options to make appropriate recommendations for patients. Additionally, understanding our clients’ perspectives is key to devising successful management plans that fit their needs and desired outcomes.
VPN Plus+ ExclusiveNon-Surgical Treatment Options for Pyometra and Pregnancy TerminationDecember 26, 2025Bruce Christensen, DVM, MS, DACT, discusses reasons for considering medical options over surgical spay for cases of canine pyometra and pregnancy termination. Dr. Christensen will then explain the available medical treatment options including protocols, efficacy, and side effects. These include prostaglandins, dopamine agonists, steroids, and progesterone receptor blockers.
Managing OA in dogs and catsDecember 23, 2025Various degrees of evidence exist for the use of various modalities in OA therapy in our canine and feline patients. Selecting therapies based on sound evidence-based veterinary medicine is paramount, as it gives the greatest likelihood of success. Ultimately, veterinarians need to combine experience and medical evidence to provide a multi-modal approach to the disease.
Canine parvo preventative gets full USDA approvalDecember 16, 2025The product, now approved as a therapeutic for canine parvovirus, marks the first USDA-approved treatment for the disease beyond supportive care and will be marketed under the name Trutect.
Managing IVDD: When to medicate, when to referDecember 16, 2025This article will review the current thinking on medical versus surgical management of IVDD, including what signs should trigger an urgent referral. With a practical grading system, recovery expectations, and client communication strategies, this guide is designed to give general practitioners confidence in handling one of the most stressful situations their clients may face.
VPN Plus+ ExclusiveLess Fear, More Hope: How Research is Driving New Strategies in Hemangiosarcoma Treatment and PreventionDecember 11, 2025In this session: Antonella Borgatti, DVM, MS, DACVIM (Oncology), DECVIM-CA, enlightens attendees with original research from the University of Minnesota on eBAT, a first-in-class bispecific targeted angiotoxin. eBAT is designed to selectively eliminate tumor cells and tumor-initiating cells, offering dual potential as both a therapeutic and preventive option in high-risk canine populations.
